Bioxtreme announced a new strategic investment led by Serra Holding, bringing its total funding to $15 million and supporting the global expansion of its AI-powered rehabilitation technologies alongside the launch of its next-generation device, Plaxtreme.
The investment will accelerate Bioxtreme’s growth across the United States and Europe, strengthen its operational footprint, and support the commercialization of Plaxtreme, a robotic system designed to improve hand and upper-limb recovery for patients with neurological conditions.
Plaxtreme combines precision robotics, immersive virtual environments, and Bioxtreme’s proprietary error augmentation technology, which amplifies movement errors to stimulate neuroplasticity and accelerate motor learning. The system also incorporates real-time AI-driven adaptation, personalized therapy adjustments, and gamified rehabilitation environments to improve patient engagement and outcomes.
The launch builds on Bioxtreme’s existing platform, including its Dextreme system for upper-limb rehabilitation, as the company expands its portfolio of technology-driven solutions aimed at restoring functional independence for patients recovering from stroke and other neurological injuries.
To support its next phase of growth, Bioxtreme has expanded its leadership team, appointing Eyal Samuel Shachar as Chief Executive Officer and Oded Lazarovich as Vice President of Product. The company also added leading experts to its Scientific Advisory Board, including James L. Patton and Franco Molteni, to guide clinical integration and international expansion.
The investment and product launch come as demand grows for advanced rehabilitation technologies that can address the increasing burden of neurological conditions through scalable, data-driven therapies.
Bioxtreme plans to showcase its technologies at the AOTA INSPIRE 2026 Conference & Expo, highlighting its approach to redefining rehabilitation through AI and robotics.
KEY QUOTE:
“Bioxtreme is entering an exciting phase of growth as we expand both our leadership team and our scientific foundation. With new investment from Serra Holding, the addition of world-class scientific advisors, and the launch of Plaxtreme, we are strengthening our ability to translate cutting-edge neuroscience into rehabilitation solutions where error becomes independence, impacting the lives of patients who need it most. We’re excited for this next step in the company’s growth.”
Eyal Samuel Shachar, CEO, Bioxtreme
